Literature DB >> 26233612

Rapid elimination of Carboxy-THC in a cohort of chronic cannabis users.

John Lewis1,2, Anna Molnar1, David Allsop2, Jan Copeland2, Shanlin Fu3.   

Abstract

Urinary 11-nor-Δ(9)-tetrahydrocannabinol-9-carboxylic acid (Carboxy-THC) concentrations, normalised to creatinine output, have been demonstrated to be a useful tool in the interpretation of the results of a series of urine tests for cannabis. These tests, often termed historical data, can be used to identify potential chronic cannabis users who may present occupational health and safety risks within the workplace. Conversely, the data can also be used to support employee claims of previous regular, rather than recent, cannabis use. This study aimed at examining the mean elimination of Carboxy-THC in 37 chronic users undergoing voluntary abstinence over a 2-week period. Urine specimens were collected prior to the study and after 1 and 2 weeks of abstinence. Carboxy-THC levels in urine were measured by gas chromatography-mass spectrometry (GC-MS) following alkaline hydrolysis, organic solvent extraction and derivatisation to form its pentafluoropropionic derivative. The creatinine-normalised Carboxy-THC concentrations declined rapidly over the 2 weeks of abstinence period and the majority of chronic cannabis users (73%) reduced their urinary Carboxy-THC levels to below the 15-μg/L confirmatory cutoff within that time. The study further highlights the value of historical urinary Carboxy-THC data as a means of identifying potential occupational health and safety risks among chronic cannabis users.

Entities:  

Keywords:  Cannabis; Carboxy-THC; THCCOOH; Urine drug testing

Mesh:

Substances:

Year:  2015        PMID: 26233612     DOI: 10.1007/s00414-015-1241-z

Source DB:  PubMed          Journal:  Int J Legal Med        ISSN: 0937-9827            Impact factor:   2.686


  16 in total

Review 1.  Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use.

Authors:  Frank Musshoff; Burkhard Madea
Journal:  Ther Drug Monit       Date:  2006-04       Impact factor: 3.681

2.  Differentiating new marijuana use from residual drug excretion in occasional marijuana users.

Authors:  M A Huestis; E J Cone
Journal:  J Anal Toxicol       Date:  1998-10       Impact factor: 3.367

3.  The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress.

Authors:  David J Allsop; Melissa M Norberg; Jan Copeland; Shanlin Fu; Alan J Budney
Journal:  Drug Alcohol Depend       Date:  2011-07-02       Impact factor: 4.492

4.  Detection times of marijuana metabolites in urine by immunoassay and GC-MS.

Authors:  M A Huestis; J M Mitchell; E J Cone
Journal:  J Anal Toxicol       Date:  1995-10       Impact factor: 3.367

5.  Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana.

Authors:  M A Huestis; J M Mitchell; E J Cone
Journal:  J Anal Toxicol       Date:  1996-10       Impact factor: 3.367

6.  Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users.

Authors:  A Smith-Kielland; B Skuterud; J Mørland
Journal:  J Anal Toxicol       Date:  1999-09       Impact factor: 3.367

7.  Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.

Authors:  Ross H Lowe; Tsadik T Abraham; William D Darwin; Ronald Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2009-07-23       Impact factor: 4.492

8.  Novel automated extraction method for quantitative analysis of urinary 11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid (THC-COOH).

Authors:  Shanlin Fu; John Lewis
Journal:  J Anal Toxicol       Date:  2008-05       Impact factor: 3.367

9.  Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol. Study III. A Delta9-THC-COOH to creatinine ratio study.

Authors:  Albert D Fraser; David Worth
Journal:  Forensic Sci Int       Date:  2003-11-26       Impact factor: 2.395

10.  Quantifying the clinical significance of cannabis withdrawal.

Authors:  David J Allsop; Jan Copeland; Melissa M Norberg; Shanlin Fu; Anna Molnar; John Lewis; Alan J Budney
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more
  1 in total

1.  Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?

Authors:  Benedikt Bernd Claus; Michael Specka; Heath McAnally; Norbert Scherbaum; Fabrizio Schifano; Udo Bonnet
Journal:  Front Psychiatry       Date:  2020-12-03       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.